Cedars-Sinai Health System

NASA's SpaceX Crew-8 astronauts supported a variety of ISS National Lab-sponsored investigations including in-space manufacturing, cancer treatments, and genetic research KENNEDY SPACE CENTER, Fla., Oct. 25, 2024 /PRNewswire/ -- After seven months of living and working onboard the International Space Station (ISS), astronauts of NASA's eighth rotational SpaceX crew mission (Crew-8) splashed down safely off the coast of Florida. The mission, which is part of NASA's Commercial Crew Program, included NASA astronauts Matthew Dominick, Michael Barratt, and Jeanette Epps, as well as Roscosmos cosmonaut Alexander Grebenkin. During their mission on station, the three NASA astronauts supported dozens of research investigations sponsored by the ISS National Laboratory®. These investigations spanned many areas, including in-space production applications, life and physical sciences, and technology development, all aimed at bringing value to humanity and enabling a robust market in low Earth orbit (LEO). Below highlights a few of the ISS National Lab-sponsored projects the Crew-8 NASA astronauts worked on during their mission. Several investigations focused on in-space production applications, an increasingly important area of emphasis for the ISS National Lab and NASA. A project from Cedars Sinai Medical Center aims to establish methods to support the in-space manufacturing of stem cells, which can be matured into a wide variety of tissues. These methods will be used for future large-scale in-space biomanufacturing of stem cell-derived products, which could lead to new treatments for heart disease, neurodegenerative diseases, and many other conditions. Redwire Corporation partnered with Eli Lilly and Company and Butler University on a series of investigations leveraging Redwire's Pharmaceutical In-space Laboratory ( PIL-BOX), a platform to crystallize organic molecules in microgravity. Results from this research could lead to improved therapeutics to treat an array of conditions. These projects continue Eli Lilly's space journey, as the company has launched multiple investigations to the orbiting laboratory over the years for the benefit of patient care on Earth. The astronauts supported the third experiment in a series of projects from the University of Notre Dame to improve ultra-sensitive biosensors. The biosensors can detect trace substances in liquids, including early cancer biomarkers. By using laser heating to control bubble formation in microgravity, the team improved particle collection—a key step in boosting sensor sensitivity. This research, funded by the U.S. National Science Foundation, could transform early and asymptomatic cancer detection and other medical diagnostics. The crew conducted phase two of a technology development project from Sphere Entertainment to test Big Sky—the company's new ultra-high-resolution, single-sensor camera—on the space station. In the first phase of the project, which launched in November 2022, astronauts tested a commercial off-the-shelf camera on the ISS to collect baseline information. During the second phase, the astronauts tested Big Sky to validate the camera's function, operations, and video downlink capabilities in microgravity. Big Sky is being developed by Sphere Entertainment to capture content for Sphere, the next-generation entertainment medium in Las Vegas. In the final days before their departure from the space station, the Crew-8 astronauts supported projects that recently launched on NASA's ninth rotational crew mission (Crew-9). One is a student-led project from Isabel Jiang, a recent high school graduate from Hillsborough, CA, who is now in her first year at Yale. Jiang is the winner of the 2023 Genes in Space student research competition, founded by Boeing and miniPCR bio and supported by the ISS National Lab and New England Biolabs. Jiang's experiment investigates the effect of radiation and the space environment on mechanisms for gene editing. Results could help develop methods to better protect astronauts and shed light on genetic risks for certain diseases during spaceflight. Another is an investigation from the U.S. Air Force Academy and Rhodium Scientific to compare the root growth of Arabidopsis plants, a member of the mustard family, at two different orbital altitudes. Plants grown on the space station in LEO for four to six days will be compared with similar plants grown on the recent Polaris Dawn mission, which flew in the same type of vehicle at a higher orbit for approximately the same amount of time. Results could provide insights into the production of crops for long-duration space missions and in high-radiation environments. These are just a few of the ISS National Lab-sponsored research projects conducted on the space station during this expedition. To learn more about these investigations and others, visit our launch page. Download a high-resolution image for this release: NASA's SpaceX Crew-8 About the International Space Station (ISS) National Laboratory: The International Space Station (ISS) is a one-of-a-kind laboratory that enables research and technology development not possible on Earth. As a public service enterprise, the ISS National Laboratory® allows researchers to leverage this multiuser facility to improve quality of life on Earth, mature space-based business models, advance science literacy in the future workforce, and expand a sustainable and scalable market in low Earth orbit. Through this orbiting national laboratory, research resources on the ISS are available to support non-NASA science, technology, and education initiatives from U.S. government agencies, academic institutions, and the private sector. The Center for the Advancement of Science in Space™ (CASIS™) manages the ISS National Lab, under Cooperative Agreement with NASA, facilitating access to its permanent microgravity research environment, a powerful vantage point in low Earth orbit, and the extreme and varied conditions of space. To learn more about the ISS National Lab, visit our website. As a 501(c)(3) nonprofit organization, CASIS accepts corporate and individual donations to help advance science in space for the benefit of humanity. For more information, visit our donations page. SOURCE International Space Station National Lab WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

ROCKVILLE, Md.--(BUSINESS WIRE)-- #BioTech -- LabGenomics USA has successfully acquired Integrated Molecular Diagnostics (IMD) CLIA labs, bringing the total number of its CLIA-certified labs in the U.S. to four. This acquisition strengthens LabGenomics’ strategic development and expands its diagnostic services nationwide, particularly in molecular technology. In August 2023, LabGenomics acquired QDx, a pathology-specialized lab on the East Coast, which became the company’s first CLIA-certified lab and marked its entry into the U.S. With the addition of IMD, LabGenomics now operates facilities in Berkeley, Sacramento, and Aurora, broadening its geographic reach and service offerings. IMD’s services focus on respiratory diseases, molecular diagnostics, and oncology, with a particular specialization in hematologic cancers and solid tumors. IMD also collaborates with Cedars-Sinai Molecular Lab on an NGS cancer panel for solid tumors, with plans to finalize its clinical validation and launch it as a Laboratory Developed Test (LDT). The IMD labs are fully equipped with CPT and Z codes for streamlined reimbursement, positioning LabGenomics for further service expansion. LabGenomics USA CEO, JungHee Cho, Ph.D., emphasized the synergy between the four CLIA labs on both coasts, highlighting complementary roles between QDx and IMD. Dr. Cho stated, “We are committed to pioneering the U.S. diagnostic market, aiming to introduce Korean diagnostics technologies. By launching LDT services, we expect revenue growth and cost savings.” IMD CEO Israel Villasenor added, “IMD’s molecular diagnostics program serves oncology needs in community-based hospitals. With LabGenomics USA’s financial and strategic backing, we can expand our services and reach more patients across the U.S.” Contacts LabGenomics USA Woohey Jung labgusa@labgenomics.com

FREMONT, Calif., Oct. 22, 2024 (GLOBE NEWSWIRE) -- ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical-stage biopharmaceutical company focused on innovative treatments in ophthalmology, CNS (central nervous system), and oncology/hematology, today announced the receipt of an additional $50,000 in licensing fees from AiBtl BioPharma Inc. With this payment, ABVC has received a total of $346,000 in licensing fees from its strategic partners, supporting our partner's belief in our mission. ABVC has received 23M AiBtl shares as part of the first milestone of the licensing fees and will obtain royalties up to $100M after the product launches. The payment, tied to ABVC's psychiatric disorder pipeline, which includes treatments for Major Depressive Disorder (MDD) and Attention Deficit Hyperactivity Disorder (ADHD), is part of a broader agreement with AiBtl BioPharma. The MDD and ADHD pipeline, valued at $667M by third-party evaluators, continues to gain momentum as both companies advance their collaborative efforts towards discussion with big pharma for out-licensing and initiating the plan for the GAP-certified temperature-controlled farm. "We are thrilled to see this consistent financial backing from our partners, reflecting confidence in the potential of our therapeutic programs," said Uttam Patil, Ph.D., Chief Executive Officer of ABVC. "The additional $50,000 from AiBtl reinforces the trust in ABVC’s vision of developing breakthrough treatments." "This milestone payment marks the continuation of a long-term strategic collaboration, reinforcing our commitment to advancing innovative CNS treatment solutions. These payments help to validate the progress of our therapeutic pipeline and reflect our confidence in our ability to deliver value for our investors. We believe that our ongoing efforts in this space will generate returns and further strengthen our position in the biopharmaceutical market," said Russman Jaimes, Chief Executive Officer of AiBtl. Driving Growth in Expanding Markets ABVC BioPharma is strategically positioned in growing markets. The global MDD market is projected to grow from $11.51 billion in 2022 to $14.96 billion by 2032, with a steady CAGR of 2.8%.[1] The global ADHD treatment market is also growing, expected to increase from $15.23 billion in 2022 at a CAGR of 7.3% through 2032.[2] Additionally, the global botanical drug market, valued at $163 million in 2021, is forecasted to experience an impressive CAGR of 39% through 2030, reaching $3.2 billion.[3] For more information about ABVC and its subsidiaries, stay updated on the latest updates or visit https://abvcpharma.com. ABVC urges its shareholders to sign up on the Company's website for the latest news alerts; visit https://abvcpharma.com/?page_id=17707 About ABVC BioPharma & Its Industry ABVC BioPharma is a clinical-stage biopharmaceutical company with an active pipeline of six drugs and one medical device (ABV-1701/Vitargus®) under development. For its drug products, the Company utilizes in-licensed technology from its network of world-renowned research institutions to conduct proof-of-concept trials through Phase II of clinical development. The Company's network of research institutions includes Stanford University, University of California at San Francisco, and Cedars-Sinai Medical Center. For Vitargus®, the Company intends to conduct global clinical trials through Phase III. Forward-Looking Statements This press release contains "forward-looking statements." Such statements may be preceded by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential," or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions, and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company's control, and cannot be predicted or quantified, and, consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. None of the outcomes expressed herein are guaranteed. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) our inability to manufacture our product candidates on a commercial scale on our own, or in collaboration with third parties; (ii) difficulties in obtaining financing on commercially reasonable terms; (iii) changes in the size and nature of our competition; (iv) loss of one or more key executives or scientists; and (v) difficulties in securing regulatory approval to proceed to the next level of the clinical trials or to market our product candidates. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's filings with the Securities and Exchange Commission (SEC), including the Company's Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors are urged to read these documents free of charge on the SEC's website at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise. This press release does not constitute an offer to sell, or the solicitation of an offer to buy any of the Company's securities, nor shall such securities be offered or sold in the United States absent registration or an applicable exemption from registration, nor shall there be any offer, solicitation or sale of any of the Company's securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction. Contact:Dr. Uttam PatilEmail: uttam@ambrivis.com [1] https://www.futuremarketinsights.com/reports/major-depressive-disorder-treatment-market#:~:text=The%20major%20depressive%20disorder%20(MDD,US%24%2011.51%20billion%20in%202022[2] https://www.polarismarketresearch.com/industry-analysis/attention-deficit-hyperactivity-disorder-market[3] https://straitsresearch.com/report/botanical-drugs-market